IDEAYA Biosciences Inc
For the period ended Dec 31, 2024. Filed Feb 18, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 18, 2025
IDYA$32.03+2.5%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Cash Flows
(in thousands)
| Year Ended December 31, | |||
|---|---|---|---|
| 2024 | 2023 | 2022 | |
| Cash flows from operating activities | |||
| Net loss | $(274,477) | $(112,961) | $(58,655) |
| Adjustments to reconcile net loss to net cash used in operating activities | |||
| Depreciation and amortization | 2,387 | 2,476 | 2,101 |
| Net amortization (accretion) of premiums (discounts) on marketable securities | (23,233) | (11,553) | (695) |
| Stock-based compensation | 34,746 | 18,489 | 11,629 |
| Amortization of right of use assets | 1,447 | 1,532 | 1,414 |
| Changes in assets and liabilities | |||
| Accounts receivable | 15 | 193 | 892 |
| Prepaid expenses and other assets | (6,174) | (2,045) | (2,119) |
| Accounts payable | 8,280 | 2,635 | 1,864 |
| Accrued and other liabilities | 10,794 | 1,635 | 4,572 |
| Contract liabilities | — | (13,753) | (46,479) |
| Lease liabilities | (1,369) | (1,872) | (1,699) |
| Net cash used in operating activities | (247,584) | (115,224) | (87,175) |
| Cash flows from investing activities | |||
| Purchases of property and equipment, net | (3,857) | (2,368) | (3,443) |
| Purchases of marketable securities | (1,191,309) | (595,980) | (255,808) |
| Maturities of marketable securities | 692,607 | 439,892 | 225,847 |
| Net cash used in investing activities | (502,559) | (158,456) | (33,404) |
| Cash flows from financing activities | |||
| Proceeds from issuance of common stock in public offering, net of issuance costs | 274,350 | 281,165 | 86,105 |
| Proceeds from issuances of pre-funded warrants | 9,400 | 42,182 | — |
| Proceeds from issuance of common stock related to at-the-market offering program, net of issuance costs | 379,879 | 28,598 | 8,857 |
| Proceeds from exercise of common stock options | 12,483 | 9,559 | 1,448 |
| Proceeds from ESPP purchases | 1,439 | 1,213 | 755 |
| Net cash provided by financing activities | 677,551 | 362,717 | 97,165 |
| Net (decrease) increase in cash, cash equivalents and restricted cash | (72,592) | 89,037 | (23,414) |
| Cash, cash equivalents and restricted cash | |||
| Cash, cash equivalents and restricted cash, at beginning of period | 157,775 | 68,738 | 92,152 |
| Cash, cash equivalents and restricted cash, at end of period | $85,183 | $157,775 | $68,738 |
| Reconciliation of cash, cash equivalents and restricted cash | |||
| Cash and cash equivalents | $84,378 | $157,018 | $68,632 |
| Restricted cash | 805 | 757 | 106 |
| Cash, cash equivalents and restricted cash | $85,183 | $157,775 | $68,738 |
| Supplemental disclosure of cash flow information: | |||
| Cash paid for interest | $25 | $69 | $60 |
| Supplemental non-cash investing and financing activities: | |||
| Right-of-use asset obtained in exchange for a new operating lease liability | $17,976 | $1,294 | $— |
| Purchases of property and equipment in accounts payable and accrued liabilities | 1,479 | 147 | 384 |
| Unpaid offering costs | — | 43 | 39 |
| Unpaid at-the-market offering program costs | $13 | $— | $— |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.